Illumina shareholders vote to install Carl Icahn board nominee, oust chair

Carl Icahn has accused Illumina's management and board of poor oversight, particularly with regard to the company's acquisition of cancer test maker Grail.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.